Unlocking the Potential of AYUSH in Global Health

The 2026-27 Union Budget and the India-EU Free Trade Agreement (FTA) together mark a transformative phase for India’s traditional medicine systems under AYUSH. Domestically, the near doubling of the AYUSH Ministry’s budget to ₹4,408 crore and the establishment of three new All-India Institutes of Ayurveda signal a shift from viewing traditional medicine as peripheral to integrating it into the mainstream healthcare system. These institutes are envisioned not only as treatment centres but also as hubs for research, education, and standard-setting, akin to AIIMS in modern medicine.

On the global front, the India-EU FTA provides unprecedented opportunities for AYUSH systems to expand internationally. It allows Indian practitioners to offer services in EU countries lacking specific regulations for traditional medicine and facilitates the establishment of Ayurvedic clinics abroad. Importantly, the agreement opens pathways for mutual recognition of safety certifications, potentially reducing regulatory barriers for AYUSH products in European markets.

Together, these developments represent a dual strategy of domestic consolidation and global outreach. However, this expansion also subjects AYUSH systems to stricter international scrutiny, making it essential to align traditional practices with global standards of safety, efficacy, and quality.

Scientific validation is critical for the global acceptance of AYUSH systems because international markets operate within rigorous regulatory and evidence-based frameworks. As Ayurveda and other traditional systems move beyond local and cultural contexts into global healthcare systems, they must demonstrate safety, efficacy, and consistency through scientifically verifiable data. Without such validation, claims made by these systems risk being dismissed as anecdotal or unsubstantiated.

Another important reason is the need to avoid reputational and legal risks. If AYUSH products or treatments fail to meet international standards, India could face legal disputes, regulatory bans, and damage to its global credibility. For instance, pharmaceutical and herbal products in the European Union are subject to stringent testing and quality control measures. Failure to comply could reinforce stereotypes about traditional medicine being unscientific.

Furthermore, scientific validation does not undermine tradition but strengthens it. Independent clinical trials, peer-reviewed research, and transparent methodologies can help identify both the strengths and limitations of AYUSH systems. This approach ensures that global expansion is based on evidence and credibility, rather than cultural assertion alone.

India can achieve regulatory harmonisation for AYUSH products by aligning its domestic standards with international norms related to safety, quality, and efficacy. This involves strengthening Good Manufacturing Practices (GMP), standardising formulations, and ensuring consistent quality across production batches. Upgrading drug-testing laboratories under the National AYUSH Mission is a step in this direction, as it enhances the credibility of certification processes.

Another key measure is promoting independent and transparent research. Currently, many studies on AYUSH systems are funded or overseen by the same institutions that promote them, leading to potential conflicts of interest. Establishing independent research bodies and collaborating with international institutions can help generate unbiased evidence that meets global standards.

Additionally, India must engage in mutual recognition agreements and continuous dialogue with regulatory authorities in partner countries. For example, the India-EU FTA’s provision for recognizing Indian safety certifications can be operationalized through technical cooperation and data sharing. This multi-pronged approach will help integrate AYUSH into global markets while maintaining regulatory integrity.

The integration of AYUSH into the mainstream healthcare system is driven by multiple factors, including rising healthcare demand, cost considerations, and holistic health approaches. India faces a significant burden on its public health infrastructure, and AYUSH systems offer complementary solutions that can reduce pressure on conventional medical facilities. For instance, incorporating AYUSH clinics within government hospitals expands access to care, particularly in underserved areas.

Another reason is the increasing global and domestic interest in holistic and preventive healthcare. Systems like Ayurveda emphasize balance, lifestyle, and long-term well-being, which align with contemporary concerns about chronic diseases and mental health. This has led policymakers to view AYUSH not merely as an alternative but as a complementary system that can coexist with biomedicine.

Finally, there is a strategic dimension. Promoting AYUSH enhances India’s soft power and creates economic opportunities through exports of services and products. The government’s investment in institutions and infrastructure reflects a recognition that traditional knowledge can be leveraged for both public health and economic growth.

AYUSH systems, particularly Ayurveda and Yoga, have already demonstrated their potential in global healthcare markets. For instance, Yoga has gained worldwide acceptance as a preventive and wellness practice, supported by initiatives like the International Day of Yoga. Similarly, Ayurvedic products such as herbal supplements and wellness therapies are increasingly popular in Europe and North America.

Under the India-EU FTA, Indian companies can establish Ayurvedic clinics in Europe, offering therapies such as Panchakarma. This creates opportunities for medical tourism and cross-border healthcare services. Additionally, the potential recognition of Indian safety certifications could allow Ayurvedic products to enter EU markets with fewer regulatory hurdles, boosting exports.

However, these opportunities also come with responsibilities. For example, if an Ayurvedic formulation claims to treat a specific condition, it must be backed by clinical evidence to meet international standards. Successful integration into global markets will depend on combining traditional knowledge with modern scientific validation, ensuring both authenticity and credibility.

The debate between traditional knowledge and scientific evidence is central to the global positioning of AYUSH systems. On one hand, proponents argue that systems like Ayurveda are based on centuries of empirical practice and offer holistic approaches to health. These systems view the body as an interconnected entity influenced by environment, diet, and lifestyle, providing insights that complement modern medicine.

On the other hand, critics emphasize the need for rigorous scientific validation. Without standardized clinical trials and peer-reviewed evidence, it becomes difficult to assess the efficacy and safety of treatments. The lack of independent research and potential conflicts of interest in existing studies further complicate the issue.

A balanced approach is required. Scientific evaluation should not be seen as a rejection of tradition but as a means to strengthen it. By subjecting AYUSH systems to rigorous testing, their effective components can be validated and integrated into mainstream medicine. This dialogue between tradition and science can lead to a more comprehensive understanding of health, benefiting both systems.

The expansion of Ayurveda under the India-EU FTA serves as a compelling case study in global health diplomacy. By incorporating provisions that allow Indian practitioners to operate in Europe and facilitating the entry of AYUSH products into EU markets, the agreement goes beyond trade to include cultural and healthcare dimensions. It reflects India’s effort to project its traditional knowledge systems as part of its global identity.

This case also highlights the challenges of aligning diverse regulatory frameworks. The EU’s stringent standards for safety and efficacy require India to upgrade its regulatory and research mechanisms. The success of this initiative will depend on India’s ability to meet these standards while preserving the authenticity of its traditional practices.

From a broader perspective, the FTA demonstrates how health systems can become tools of soft power and economic engagement. If successful, it could pave the way for similar agreements with other regions, positioning India as a leader in traditional and integrative medicine. However, sustained success will require a commitment to evidence-based practices and international collaboration.